New translational data will be presented for BT1718, the Company’s lead Bicycle® Toxin Conjugate (BTC) product candidate, which define enrollment criteria for identifying expansion cohorts in the Phase IIa part of the ongoing Phase I/IIa trial with BT1718. The Phase I/IIa study, sponsored by
“We are creating a pipeline of Bicycle Toxin Conjugates, which selectively deliver toxin payload to tumors in a manner we believe is unique and differentiated to that of antibody drug conjugates,” said
Additional preclinical data will also be presented for Bicycle’s other BTC programs, BT5528 and BT8009, which show target-dependent anti-tumor activity across a range of EphA2-expressing and Nectin-4-expressing cancer models, respectively.
Details on Bicycle’s presentations at AACR-NCI-EORTC are as follows:
Session Title: Poster Session A
Location: Level 2, Hall D
Poster Presentation Title: MT1-MMP Immunohistochemistry (IHC) analysis of tumor microarrays (TMAs) using a novel scoring system guides patient selection for BT1718 expansion cohorts
Abstract #: A047
Date & Time:
Session Title: Poster Session C
Location: Level 2, Hall D
Poster Presentation Title: BT5528, a Bicycle Toxin Conjugate targeting EphA2: mechanism of action and clinical translation
Abstract #: C066
Date & Time:
Session Title: Poster Session C
Location: Level 2, Hall D
Poster Presentation Title: BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models
Abstract #: C061
Date & Time:
The posters will be available on the Publications section of bicycletherapeutics.com following the presentation.
About BT1718
BT1718 is a Bicycle® Toxin Conjugate being developed by
About
About Cancer Research UK’s Centre for Drug Development
About
-
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. - Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
-
Cancer Research UK receives no funding from theUK government for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public. -
Cancer Research UK has been at the heart of the progress that has already seen survival in theUK double in the last 40 years. - Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
-
Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses. -
Together with its partners and supporters,
Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the clinical development of BT1718 or any of Bicycle’s other product candidates or programs, the progression of Bicycle’s ongoing Phase I/IIa clinical trial of BT1718 into Phase IIa, the expected cohort composition of the Phase IIa expansion of this clinical trial, and the anticipated dose selection in this clinical trial. Bicycle may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Bicycle’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of BT1718 or other product candidates; risks related to Bicycle’s ability to maintain existing collaborations and realize the benefits thereof; expectations for regulatory approvals to conduct trials or to market product; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, as described in greater detail in the section entitled “Risk Factors” in the final prospectus for our initial public offering, filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20191016005898/en/
Source:
Investors:
Bicycle Therapeutics
Maren Killackey
maren.killackey@bicycletx.com
+1-617-203-8300
Media:
Ten Bridge Communications
Sara Green
sgreen@tenbridgecommunications.com
+1-617-233-1714